Business
Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity - two common nerve agents
Nexien BioPharma announces that it has been granted a patent by the Israeli Patent Office covering the use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity - two common nerve agents.
About this update from Nexien Biopharma, Inc.
[{"type":"text","content":"\nNexien BioPharma, Inc. (“Nexien” or the “Company”) (OTCQB: NXEN), a next generation biopharmaceutical company focused on research, development and commercialization of novel FDA-compliant cannabinoid pharmaceuticals and related drug delivery systems, today announced that it was granted Patent No. 238946 for “Use of Cannabinoids and Terpenes for Treatment of Organophosphate and Carbamate Toxicity” by the Israeli Patent Office.\n\n\nThe endocannabinoid system and other physiological systems can potentially mitigate the effects of organophosphate and carbamate toxicity when treated with medicaments affecting these systems in a time and dose-dependent format.\n\n\nNexien’s unique process for treating symptoms incorporates a composition comprising tetrahydrocannabinol and cannabidiol formulated for administration by an oral, nasal, buccal, sublingual, parenteral, or any combination thereof.\n\n\nAlex Wasyl, Nexien’s Chief Executive Officer, stated, “We are pleased to announce a milestone in Nexien’s patent development - the granting of our first patent in Israel. While we continue to build our entire patent estate, this achievement puts Nexien in a better position to advance our clinical investigation of cannabinoid drug formulations and delivery systems for the acute treatment during exposure of poisoning from organophosphorus nerve agents.”\n\n\nAbout Organophosphate and Carbamate Toxicity\n\n\nOrganophosphate and carbamate compounds are typically used as insecticides, pesticides, petroleum additives and petrochemicals. Organophosphate and carbamate have also been developed for use as chemical warfare nerve agents, such as Sarin. While some of these compounds are banned in developed countries, they are mostly inexpensive and accessible, especially in poorer countries. It is estimated that at least 750,000 cases of organophosphate poisoning occur every year with an estimated 300,000 fatalities a year world-wide.\n\n\nAbout Nexien BioPharma, Inc.\n\n\nNexien BioPharma is a US-based pharmaceutical company engaged in the formulation, development and commercialization of cannabinoid-based pharmaceuticals in accordance with U.S. Food and Drug Administration (“FDA”) pre-clinical and clinical pathways, to address a broad range of medical conditions and disorder...